Author

Stephen Gulyas

Observed name: S. Gulyas

Observed institutions: Cedars-Sinai Medical Center, Mayo Clinic, University of California, Los Angeles, Eli Lilly (United States), Pfizer (United States), Wayne State University, Hospital Clínico San Carlos, University of Alabama at Birmingham, The Barbara Ann Karmanos Cancer Institute, Los Angeles Medical Center, Eli Lilly (Canada), Hospital Nacional Edgardo Rebagliati Martins

OpenAlex ID: A5074486599

Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer

2004 · John Rinehart, Alex A. Adjei, et al. · Journal of Clinical Oncology · 643

Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study

2006 · D.A. Richards, K.A. Boehm, et al. · Annals of Oncology · 101

A Multicenter, Single-Arm Phase II Study of Pemetrexed Plus Doxorubicin Administered Every 21 Days in Patients With Advanced Breast Cancer

2009 · Miguel Martin, Maria Blasinska-Morawiec, et al. · Clinical Breast Cancer · 4

A phase II study of pemetrexed and doxorubicin in patients with advanced or metastatic breast cancer (MBC)

2007 · M. Blasinska-Morawiec, M. Martin, et al. · Journal of Clinical Oncology

Works count: 5

Citation count: 748

H-index: 3

I10-index: 2